SOFINICLINE BESYLATE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H11Cl2N3.C6H6O3S
Molecular Weight	402.295
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(=O)(=O)C1=CC=CC=C1.ClC2=C(Cl)N=CC(=C2)N3C[C@@H]4CN[C@@H]4C3

InChI

InChIKey=QDWNBBFBKYGQFG-RDNZEXAOSA-N

InChI=1S/C10H11Cl2N3.C6H6O3S/c11-8-1-7(3-14-10(8)12)15-4-6-2-13-9(6)5-15;7-10(8,9)6-4-2-1-3-5-6/h1,3,6,9,13H,2,4-5H2;1-5H,(H,7,8,9)/t6-,9+;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C6H6O3S
Molecular Weight	158.175
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C10H11Cl2N3
Molecular Weight	244.12
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://adisinsight.springer.com/drugs/800019709 | https://www.ncbi.nlm.nih.gov/pubmed/24965900

Sofinicline is a selective agonist of the a4b2 subtype of nAChR. It is under development by Abbott Laboratories in collaboration with NeuroSearch. It is produced as a capsule in doses of 1, 2 or 4 mg. Sofinicline is a full agonist of the a4b2 nAChR. It has high binding affinity, ~ 0.1 nM, for this receptor. Sofinicline is orally active and is metabolized hepatically. Sofinicline has been used in trials studying the treatment of ADHD, neuralgia, diabetic neuropathies, diabetic polyneuropathy, and diabetic neuropathic pain, among others.

Originator

Approval Year

PubMed

Title	Date	PubMed
Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder.	2014-08	24965900
Metabolism and disposition of ABT-894, a novel α4β2 neuronal acetylcholine receptor agonist, in mice and monkeys.	2014-06	24479584

Patents

Sample Use Guides

In Vivo Use Guide

Analgesic efficacy and safety of Sofinicline (ABT-894) was evaluated in 2 randomized, double-blind, multicenter, placebo-controlled clinical trials in patients with diabetic peripheral neuropathic pain (DPNP). Study 1 (280 patients randomized) tested 1, 2, and 4 mg ABT-894 twice daily compared with placebo and 60 mg duloxetine once per day over 8 weeks of treatment. Study 2 (124 patients randomized) tested 6 mg ABT-894 twice daily vs placebo for 8 weeks. A sofinicline dose of 4 mg orally twice a day, at steady state, produced a Cmax of 11 - 15 ng/ml.

Route of Administration: Oral

In Vitro Use Guide

Sofinicline is a full agonist of the a4b2 nAChR. It has high binding affinity, ~ 0.1 nM, for this receptor.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:32:40 GMT 2025` Edited by `admin` on `Mon Mar 31 18:32:40 GMT 2025`
Record UNII	G889I438OQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SOFINICLINE BESYLATE

Common Name

English

SOFINICLINE BENZENESULFONATE

Preferred Name

English

A-422894.112

Code

English

SOFINICLINE BESILATE

Common Name

English

SOFINICLINE BESYLATE [USAN]

Common Name

English

(-)-(1S,5S)-3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO(3.2.0)HEPTANE MONOBENZENESULFONATE

Systematic Name

English

(-)-(1S,5S)-3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO(3.2.0)HEPTANE MONOBENZENESULPHONATE

Systematic Name

English

SOFINICLINE BENZENESULPHONATE

Common Name

English

3,6-DIAZABICYCLO(3.2.0)HEPTANE, 3-(5,6-DICHLORO-3-PYRIDINYL)-, (1S,5S)-, MONOBENZENESULPHONATE

Systematic Name

English

3,6-DIAZABICYCLO(3.2.0)HEPTANE, 3-(5,6-DICHLORO-3-PYRIDINYL)-, (1S,5S)-, MONOBENZENESULFONATE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C73579